LEADER 04994nam 22005535 450 001 9910350356603321 005 20200630033201.0 010 $a981-13-7387-6 024 7 $a10.1007/978-981-13-7387-9 035 $a(CKB)4100000008876788 035 $a(DE-He213)978-981-13-7387-9 035 $a(MiAaPQ)EBC5780784 035 $a(PPN)236520881 035 $a(EXLCZ)994100000008876788 100 $a20190527d2019 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHigh-Density Lipoproteins as Biomarkers and Therapeutic Tools $eVolume 1. Impacts of Lifestyle, Diseases, and Environmental Stressors on HDL /$fby Kyung-Hyun Cho 205 $a1st ed. 2019. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2019. 215 $a1 online resource (XXIV, 383 p. 244 illus.) 311 $a981-13-7386-8 327 $aPreface -- Chapter 1. Understanding HDL: overview -- 1-1.HDL and disease -- 1-2.HDL functions and clinical applications -- 1-3.HDL composition : apolipoproteins and enzymes -- 1-4.Maturation of HDL -- 1-5.HDL and blood pressure -- Chapter 2. Change of HDL by life style -- 2-1.Exercise and HDL -- 2-2.Smoking and HDL -- 2-3.Elderly?s HDL -- 2-4.HDL depends on body weight -- 2-5.HDL from obese but healthy subject -- 2-6.HDL and apoA-I in smokers? breast milk -- 2-7.Breast milk from frequent trans fatty acid consumers -- 2-8.HDL in cord blood from small neonates -- Chapter 3. Change of HDL in various diseases -- 3-1.HDL from patients with myocardial infarction -- 3-2.HDL from patients with female angina pectoris -- 3-3.HDL and metabolic syndrome -- 3-4.HDL from male patients with atrial fibrillation -- 3-5.HDL from female patients with atrial fibrillation -- 3-6.HDL from patients with hemorrhagic fever with renal syndrome -- 3-7.HDL from patients with rheumatoid arthritis -- 3-8.HDL and prehypertension -- Chapter 4. Detriment of HDL by pollutant and its evaluation -- 4-1.Particulate matter and HDL -- 4-2.Phthalate and HDL -- 4-3.Cadmium and HDL -- 4-4.Humidifier Sterilizer and HDL -- 4-5.Detection of dysfunctional HDL by microfluidics -- 4-6.Evaluation of dysfunctional HDL using zebrafish embryo -- Chapter 5. Change of HDL by food ingredient -- 5-1.Fructose and apoA-I -- 5-2.Fructose and impairment of HDL functionality -- 5-3.Artificial sweeteners and apoA-I -- 5-4.Artificial sweeteners (aspartame, saccharin) and HDL -- 5-5.Aldoketohexoses and HDL -- 5-6.Iron and HDL -- 5-7.Trans fat and HDL -- 5-8.Salt and HDL 576 p -- Summary and perspectives. 330 $aThis book is the first of two volumes that offer a comprehensive, up-to-date account of current knowledge regarding high-density lipoprotein (HDL), the changes that occur in HDL under different conditions, the clinical applications of HDL, and means of enhancing HDL functionality. HDL comprises a diverse group of lipoproteins and its composition and metabolism are dynamic. In this volume, the focus is on the changes observed in HDL under different health statuses, with particular attention to the functional and structural correlations of HDL and apolipoprotein A-1. The impacts of a wide variety of factors on HDL are examined in depth, covering, for example, diet, exercise, smoking, age, diverse diseases, and different forms of environmental pollution. It has long been known that HDL has anti-atherosclerotic and antidiabetic properties, and more recently its anti-aging activities have been recognized. These benefits of HDL are highly dependent on its lipids, proteins, apolipoproteins, and enzymes, and specifically their composition and ratios. In documenting the latest knowledge in this field, this volume will be of interest to both researchers and clinicians. 606 $aMolecular biology 606 $aPharmaceutical technology 606 $aBiomedical engineering 606 $aDiabetes 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aBiomedical Engineering/Biotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/B24000 606 $aDiabetes$3https://scigraph.springernature.com/ontologies/product-market-codes/H33045 615 0$aMolecular biology. 615 0$aPharmaceutical technology. 615 0$aBiomedical engineering. 615 0$aDiabetes. 615 14$aMolecular Medicine. 615 24$aPharmaceutical Sciences/Technology. 615 24$aBiomedical Engineering/Biotechnology. 615 24$aDiabetes. 676 $a611.01816 700 $aCho$b Kyung-Hyun$4aut$4http://id.loc.gov/vocabulary/relators/aut$0952601 906 $aBOOK 912 $a9910350356603321 996 $aHigh-Density Lipoproteins as Biomarkers and Therapeutic Tools$92153528 997 $aUNINA